Skip to main content

Animations

MJFF Publications

2801 - 2810 of 8436 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • Summary Details
    OPEN
    Title: The contribution of behavioral features to caregiver burden in FTLD spectrum disorders
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/alz.12494
    Citation Count: 22
  • Summary Details
    RESTRICTED
    Title: A brief history of nearly EV‐erything – The rise and rise of extracellular vesicles
    Journal Name: Journal of Extracellular Vesicles
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/jev2.12144
    Citation Count: 176
  • Summary Details
    RESTRICTED
    Title: Amantadine in the treatment of Parkinson's disease and other movement disorders
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00249-0
    Best OA location URL:
    Citation Count: 73
  • Summary Details
    RESTRICTED
    Title: Autophagy and the hallmarks of aging
    Journal Name: Ageing Research Reviews
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: publisher-specific-oa
    DOI - Digital Object Identifier: 10.1016/j.arr.2021.101468
    Citation Count: 115
  • Summary Details
    RESTRICTED
    Title: Corrigendum to “Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys” [EBioMedicine 2020; 59:102944]
    Journal Name: eBioMedicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.ebiom.2021.103731
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-021-00491-y
    Citation Count: 45
  • Summary Details
    RESTRICTED
    Title: Disease modifying therapies for Parkinson's disease: Novel targets
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2021.108839
    Best OA location URL:
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice
    Journal Name: Cell Reports Medicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.xcrm.2021.100455
    Citation Count: 25
  • Summary Details
    OPEN
    Title: Large‐scale deep multi‐layer analysis of Alzheimer’s disease brain reveals strong proteomic disease‐related changes not observed at the RNA level
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/alz.055041
    Citation Count: 4
  • Summary Details
    RESTRICTED
    Title: LRRK2 signaling in neurodegeneration: two decades of progress
    Journal Name: Essays in Biochemistry
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1042/ebc20210013
    Best OA location URL:
    Citation Count: 10
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.